問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Infectious Disease

Division of Pediatrics

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

謝孟亨
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝孟亨

List

31Cases

2020-06-20 - 2027-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2021-01-04 - 2026-03-31

Others

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Terminated6Sites

2025-06-16 - 2029-09-30

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study)

  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A phase IIb trial (ARGiNAUT) evaluating the efficacy, safety, and tolerability of AZD8965 in patients with idiopathic pulmonary fibrosis (IPF).

  • Condition/Disease

    Idiopathic pulmonary fibrosis

  • Test Drug

    AZD8965 Film-Coated Tablet

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-12-23 - 2024-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

  • Condition/Disease

    Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Test Drug

    NS-863

Participate Sites
6Sites

Not yet recruiting1Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A phase 2, randomized, double-blind, placebo-controlled, dose-exploration trial was conducted to evaluate the efficacy and safety of oral NS-863 in participants with pulmonary arterial hypertension (PAH).

  • Condition/Disease

    Pulmonary hypertension

  • Test Drug

    NS-863

Participate Sites
5Sites

Not yet recruiting1Sites

2022-09-30 - 2026-04-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2025-10-01 - 2028-12-31

Active
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

  • Condition/Disease

    Bronchiectasis With Pseudomonas Aeruginosa Colonization

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

  • Condition/Disease

    Severe Asthma

  • Test Drug

    GB-0895

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB